by Sameer Laul | Jan 9, 2023 | News
EpiVax, Inc. is excited to announce that its subsidiary, EpiVax Therapeutics, has signed an exclusive collaboration agreement with GreenLight Biosciences to advance the development of personalized cancer vaccines. The effort will combine GreenLight’s mRNA...
by Sameer Laul | Jan 6, 2023 | News
“I have found that among its other benefits, giving liberates the soul of the giver.” – Maya Angelou EpiVax’s VaxGivesBack Fund kicked the holiday off by partnering with AIDS Care Ocean State and Clinica Esperanza/Hope Clinic to distribute gifts to local...
by Riley Nolan | Oct 31, 2022 | Featured, News
EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine PROVIDENCE, RI, October 31, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for...
by Riley Nolan | Sep 12, 2022 | Featured, News
PROVIDENCE, RI, September 12, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk...
by Riley Nolan | Jun 10, 2022 | Featured, News
PROVIDENCE, RI, June 10, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National...
by Riley Nolan | May 25, 2022 | Featured, News
PROVIDENCE, RI, May 25, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity” in Frontiers in Immunology, a collaboration...